medRxiv
September 29, 2019
Lorenzo Pasquini, Fernanda Palhano-Fontes, Dráulio B. Araújo
24 citations
preprint
One day after a single session with the psychedelic ayahuasca, connectivity within and between brain networks that support interoception, emotion, and self-related thought is altered compared to placebo. In a randomized trial with 22 participants receiving ayahuasca and 21 receiving placebo, the ayahuasca group showed increased connectivity within the salience network, decreased connectivity within the default mode network, and increased connectivity between these two networks. Primary sensory networks were not affected. These connectivity changes correlated with acute subjective effects such as altered body awareness, volition, and affect. The findings suggest that ayahuasca induces subacute functional reorganization of higher-order cognitive brain networks.
Nature Medicine
April 1, 2026
Manesh Girn, Manoj K. Doss, Leor Roseman et al.
8 citations
Psychedelic drugs are being studied again for their therapeutic potential, but how they change brain function is not well understood. By combining 11 brain-scanning datasets from five different psychedelics (psilocybin, LSD, mescaline, DMT, and ayahuasca) across three continents, researchers found a common pattern: increased communication between brain networks that handle high-level thinking (default, frontoparietal, and limbic) and those that handle sensory input (visual and somatomotor). Key deep-brain regions (thalamus, caudate, putamen) and the cerebellum also changed how they connect with sensorimotor networks. Contrary to some earlier studies, reductions in within-network connectivity were weak to moderate and varied by drug. These findings help resolve previous inconsistencies and provide a comprehensive map of how psychedelics alter large-scale brain organization.
Chaos Solitons & Fractals
May 30, 2026
Tales Ramos Monteiro Dos Santos, Dráulio B. Araújo, Helcio Felippe et al.
Psychedelic states can help researchers understand how the brain reorganizes at a large scale. In nine people scanned before and after taking ayahuasca, topological data analysis of resting-state fMRI connectivity showed a nominal decrease in persistent entropy of H2 features—a measure of higher-dimensional topological structure—that did not survive correction for multiple comparisons and was not reproduced with signed correlations. Exploratory analyses of signal complexity found descriptive but non-significant increases. These preliminary, hypothesis-generating results highlight persistent homology as a potential framework for studying psychedelic-related brain changes, but replication in larger placebo-controlled studies is needed.
Current Addiction Reports
February 21, 2026
Dráulio B. Araújo, Lucas O. Maia, Tiago Arruda-Sanchez et al.
Preclinical and clinical evidence suggests that ayahuasca, a traditional Amazonian brew containing DMT and β-carbolines, may treat depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical studies indicate enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging shows decreased default mode network activity, increased functional connectivity and brain entropy, suggesting a flexible neural state and modulation of pathways related to neuroplasticity, inflammation, and stress response. The evidence is mainly observational, with users reporting emotional breakthroughs, increased self-awareness, and mystical experiences tied to therapeutic outcomes. Ayahuasca appears to target core psychological and neurobiological processes across disorders but requires caution in psychotic or bipolar individuals and should be administered with support. Randomized trials are needed to confirm efficacy and safety.